BioKansas - Viracor Looks to Partner with Kansas City Community on COVID-19 Testing
Viracor Eurofins has been at the forefront of fighting SARS-CoV-2 in the US, having launched testing on March 13 using polymerase chain reaction (PCR) with same or next day results for PCR, and 2-4 days for blood-based antibody testing. The laboratory’s current focus is reaching out to our local communities in Kansas and Missouri that may be in need of testing.
Viracor Partners with VA New England Veterans Healthcare System to Offer COVID-19 Testing
Viracor will offer two types of COVID-19 tests through the company’s established contract with the GSA (U.S. General Services Administration Contract):
CommonWealth - If you survive COVID-19, are you immune?
The FDA is also allowing commercial labs to run these types of tests without FDA review. Framingham-based Boston Heart Diagnostics started offering a blood test on Monday that measures COVID-19 antibodies. The test is not meant to diagnose the virus, but it can be used to determine if someone had COVID-19 in the past and whether the virus is still present.
Viracor Eurofins Receives Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its SARS-CoV-2 RT-PCR laboratory-developed test (LDT)
Viracor Eurofins, one of the largest and most recognised infectious diseases testing laboratories in the U.S., was granted an Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its Clinical Diagnostics' molecular laboratory-developed test (LDT). The Viracor SARS-CoV-2 assay is a real-time polymerase chain reaction (RT-PCR) test intended for the qualitative detection of SARS-CoV-2 viral RNA in nasopharyngeal swab, nasal swab, nasopharyngeal wash, nasal wash, oropharyngeal swab and bronchoalveolar lavage from individuals suspected of COVID-19. The Viracor EUA is available on https://www.fda.gov/media/136740/download.
The National Kidney Registry and Viracor Eurofins Announce Coronavirus Antibody Testing for Donors and Recipients
“We are pleased to announce that COVID-19 antibody testing will be available to NKR Member Centers by Friday, April 10th. Some centers are already planning to use the newly released antibody test for screening donors and recipients prior to surgery, in conjunction with the PCR test, and for research related to waitlisted patients and transplant recipients.” Said Garet Hil, Founder and CEO, National Kidney Registry. “We are grateful for the rapid response from Eurofins in developing this solution and we indebted to key members of our Medical Board for guiding us through this process.
NPR Boston - Eurofins' Boston Heart Diagnostics Lab Launches Rapid Test for Telltale Coronavirus Antibodies
The COVID-19 blood-based serology test looks for a type of antibodies that reflect having had active disease, and it's thought the best time to test for them is at 14 days after infection. The lab hopes to participate in research with local hospitals to monitor patients' immune response over time and possibly to help with efforts to develop treatments from antibodies.